| Filed On | Filing |
|---|---|
| 21 Oct 2026 | EFFECT |
| 21 Oct 2026 | 424B3 |
| 21 Oct 2026 | S-4/A |
| 09 Oct 2026 | S-4/A |
| 05 Oct 2026 | 425 |
| 05 Oct 2026 |
8-K: Regulation FD Disclosure
Boston, Mass., October, 5, 2026 – Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED (“ARCHIMED”), a leadi... |
| 30 Sep 2026 | 425 |
| 30 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
| 09 Sep 2026 | S-4/A |
| 24 Aug 2026 |
Form 4: Mackay Sean, SVP & Chief Business Officer
Gave up 25,729 shares to cover exercise price or tax ($17.3K) |
| 24 Aug 2026 |
Form 4: Kim Hanjoon Alex, Chief Financial Officer
Gave up 28,195 shares to cover exercise price or tax ($18.9K) |
| 24 Aug 2026 |
Form 4: Egholm Michael, Director
Gave up 97,627 shares to cover exercise price or tax ($65.6K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G |
| 05 Aug 2026 | FORM S-8 |
| 05 Aug 2026 | FORM S-8 |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 04 Aug 2026 |
Form 4: Egholm Michael, Director
Gave up 362,625 shares to cover exercise price or tax ($315K) |
| 30 Jul 2026 | SCHEDULE 13G/A |
Loading...
